Table 1. Cellular composition and chimerism of recipient mice transplanted in a competitive manner and analyzed 16 wk later.
Parameter | Group 1 | Group 2 | Group 3 | |||||
---|---|---|---|---|---|---|---|---|
Ly5.1+: Ad5-Venus; Ly5.2+: Ad5-Venus | P-value | Ly5.1+: Ad5-Venus; Ly5.2+: Ad5–BCL-XL | P-value | Ly5.1+: Ad5-Venus; Ly5.2+: untreated | P-value | |||
BM | ||||||||
Cells (×107) | 5.83 ± 0.46 | 6.91 ± 0.31 | 8.08 ± 0.61 | |||||
Monocytes (×106) | 13.20 ± 1.13 | 15.32 ± 1.49 | 16.86 ± 1.30 | |||||
Granulocytes (×106) | 13.68 ± 2.56 | 16.55 ± 2.78 | 17.56 ± 2.92 | |||||
B220+IgM− B cells (×106) | 8.49 ± 1.08 | 9.56 ± 1.17 | 14.75 ± 1.72 | |||||
IgM+ B cells (×106) | 5.32 ± 2.98 | 4.90 ± 2.55 | 6.97 ± 3.31 | |||||
CD4+ T cells (×106) | 1.42 ± 0.19 | 1.60 ± 0.14 | 1.93 ± 0.21 | |||||
CD8+ T cells (×106) | 1.19 ± 0.15 | 1.40 ± 0.12 | 1.47 ± 0.23 | |||||
Ly5.1+ monocytes (%) | 20.08 ± 8.2 | 0.87 | 20.01 ± 8.1 | 0.07 | 9.97 ± 4.0 | 0.02 | ||
Ly5.2+ monocytes (%) | 20.85 ± 9.6 | 52.95 ± 7.4 | 57.55 ± 9.5 | |||||
Ly5.1+ granulocytes (%) | 45.08 ± 6.9 | 0.06 | 24.51 ± 5.5 | 0.58 | 17.50 ± 4.6 | 0.09 | ||
Ly5.2+ granulocytes (%) | 11.86 ± 6.4 | 34.30 ± 7.0 | 34.86 ± 6.8 | |||||
Ly5.1+ B220+IgM− cells (%) | 27.30 ± 9.2 | 0.87 | 18.65 ± 6.7 | 0.04 | 15.98 ± 5.5 | 0.04 | ||
Ly5.2+ B220+IgM− cells (%) | 23.01 ± 7.6 | 50,51 ± 6.4 | 48.36 ± 6.1 | |||||
Ly5.1+ B220+IgM+ cells (%) | 26.27 ± 10.1 | 0.87 | 15.61 ± 7.1 | 0.04 | 14.04 ± 5.1 | 0.03 | ||
Ly5.2+ B220+IgM+ cells (%) | 21.00 ± 7.3 | 40.64 ± 5.5 | 46.68 ± 5.4 | |||||
Ly5.1+ CD4+ cells (%) | 11.92 ± 3.9 | 0.40 | 10.64 ± 3.5 | 0.02 | 8.87 ± 3.2 | 0.03 | ||
Ly5.2+ CD4+ cells (%) | 19.05 ± 5.3 | 40.98 ± 5.5 | 36.25 ± 5.8 | |||||
Ly5.1+ CD8+ cells (%) | 13.94 ± 5.1 | 0.24 | 8.68 ± 2.7 | 0.01 | 5.45 ± 2.0 | 0.01 | ||
Ly5.2+ CD8+ cells (%) | 28.15 ± 7.5 | 55.16 ± 7.5 | 39.33 ± 8.1 | |||||
Spleen | ||||||||
Cells (×107) | 6.13 ± 1.30 | 7.91 ± 1.12 | 8.22 ± 1.50 | |||||
Monocytes (×106) | 3.08 ± 0.49 | 3.55 ± 0.55 | 3.65 ± 0.31 | |||||
Granulocyte (×106) | 1.42 ± 0.33 | 1.49 ± 0.30 | 1.47 ± 0.35 | |||||
B220+IgM− B cells (×106) | 16.8 ± 5.5 | 23.2 ± 5.1 | 23.8 ± 5.6 | |||||
IgM+ B cells (×106) | 17.6 ± 1.11 | 20.6 ± 1.03 | 26.2 ± 1.51 | |||||
CD4+ T cells (×106) | 12.3 ± 2.3 | 15.4 ± 2.7 | 16.5 ± 3.1 | |||||
CD8+ T cells (×106) | 5.70 ± 1.18 | 7.04 ± 1.43 | 6.52 ± 1.25 | |||||
Thymus | ||||||||
Cells (×107) | 3.76 ± 0.99 | 4.43 ± 0.54 | 4.44 ± 0.83 | |||||
DN cells (×106) | 1.10 ± 0.29 | 1.72 ± 0.14 | 1.64 ± 0.38 | |||||
DP cells (×106) | 27.4 ± 8.6 | 29.4 ± 5.8 | 30.2 ± 7.4 | |||||
CD4+ SP cells (×106) | 4.62 ± 1.10 | 6.10 ± 0.95 | 5.69 ± 1.12 | |||||
CD8+ SP cells (×106) | 0.99 ± 0.24 | 1.52 ± 0.20 | 1.56 ± 0.36 | |||||
Ly5.1+ DN cells (%) | 28.72 ± 10.4 | 0.50 | 15.19 ± 7.1 | 0.02 | 14.57 ± 5.7 | 0.03 | ||
Ly5.2+ DN cells (%) | 36.04 ± 8.7 | 47.41 ± 6.8 | 53.70 ± 7.0 | |||||
Ly5.1+ DP cells (%) | 41.55 ± 14.6 | 0.74 | 17.37 ± 9.2 | 0.05 | 14.82 ± 7.0 | 0.07 | ||
Ly5.2+ DP cells (%) | 29.23 ± 10.7 | 58.46 ± 8.4 | 57.40 ± 11.3 | |||||
Ly5.1+ CD4+ SP cells (%) | 39.55 ± 13.1 | 0.87 | 17.19 ± 7.9 | 0.04 | 19.40 ± 7.7 | 0.07 | ||
Ly5.2+ CD4+ SP cells (%) | 35.62 ± 11.2 | 58.01 ± 7.4 | 54.84 ± 10.9 | |||||
Ly5.1+ CD8+ SP cells (%) | 25.08 ± 11.0 | 0.24 | 9.70 ± 4.5 | 0.01 | 8.66 ± 3.2 | 0.01 | ||
Ly5.2+ CD8+ SP cells (%) | 47.69 ± 12.8 | 71.70 ± 7.3 | 65.93 ± 9.9 | |||||
Blood | ||||||||
Cells (/µl) | 5,593 ± 10.21 | 6,436 ± 10.81 | 6,584 ± 9.64 | |||||
Monocytes (/µl) | 379 ± 71 | 610 ± 153 | 361 ± 42 | |||||
Granulocytes (/µl) | 702 ± 104 | 1,240 ± 358 | 527 ± 96 | |||||
B220+IgM− B cells (/µl) | 1,175 ± 363 | 2,154 ± 333 | 1,817 ± 279 | |||||
IgM+ B cells (/µl) | 60 ± 38 | 44 ± 17 | 62 ± 28 | |||||
CD4+ T cells (/µl) | 891 ± 142 | 1,089 ± 144 | 865 ± 91 | |||||
CD8+ T cells (/µl) | 526 ± 104 | 641 ± 92 | 475 ± 60 | |||||
Ly5.1+ monocytes (%) | 23.43 ± 8.8 | 0.87 | 26.47 ± 11.8 | 0.26 | 10.27 ± 4.1 | 0.01 | ||
Ly5.2+ monocytes (%) | 21.20 ± 8.0 | 50.56 ± 8.0 | 60.36 ± 9.9 | |||||
Ly5.1+ granulocytes (%) | 56.70 ± 8.9 | 0.04 | 32.54 ± 8.9 | 0.58 | 25.50 ± 7.0 | 0.26 | ||
Ly5.2+ granulocytes (%) | 15.25 ± 6.5 | 38.59 ± 6.6 | 42.54 ± 7.6 | |||||
Ly5.1+ B220+IgM− cells (%) | 25.28 ± 9.7 | 0.61 | 20.64 ± 6.8 | 0.03 | 16.42 ± 6.8 | 0.03 | ||
Ly5.2+ B220+IgM− cells (%) | 36.30 ± 11.3 | 57.08 ± 7.0 | 62.93 ± 8.0 | |||||
Ly5.1+ B220+IgM+ cells (%) | 38.38 ± 13.1 | 0.47 | 25.37 ± 8.5 | 0.22 | 23.39 ± 8.9 | 0.08 | ||
Ly5.2+ B220+IgM+ cells (%) | 27.41 ± 13.7 | 53.97 ± 10.9 | 52.57 ± 10.3 | |||||
Ly5.1+ CD4+ cells (%) | 28.06 ± 12.1 | 0.61 | 19.32 ± 6.8 | 0.07 | 17.67 ± 4.9 | 0.04 | ||
Ly5.2+ CD4+ cells (%) | 30.01 ± 11.4 | 49.75 ± 6.4 | 49.37 ± 7.2 | |||||
Ly5.1+ CD8+ cells (%) | 19.60 ± 8.3 | 0.40 | 13.16 ± 4.5 | 0.02 | 9.95 ± 3.2 | 0.01 | ||
Ly5.2+ CD8+ cells (%) | 31.08 ± 8.8 | 52.66 ± 7.0 | 46.37 ± 7.3 |
The transplantation procedure and groups are defined in Fig. 3. Values represent means of n = 7–8 animals from three independent experiments ± SEM. Significant p-values with regard to the Ly5.1+/Ly5.2+ ratio are indicated (Wilcoxon test). DN, double negative; DP, double positive; SP, single positive.